论文部分内容阅读
例1 女性,34岁,诊断非何杰金氏淋巴瘤(NHL)3年半。病理:弥漫性大小细胞混合型非何杰金氏淋巴瘤。曾行CHOP方案化疗2周期,达完全缓解(CR)后未再治疗。20个月前颈部两侧淋巴结肿大,病理同前。先后行CHOP方案和PYM—CHOP方案化疗10周期,并在半年前行局部放疗,均未达CR。在常规化疗效果不佳情况下决定应用G—CSF(惠尔血)支持行超大剂量化疗。方案为BEOD—CTX。具体用药如下:CTX;2.0、第1～13天,静点(Mesna保护肾脏);VCR:1.5mg、第1天,静注;BCNU:375mg、第1天、静点;V_p—16:100mg、
Example 1 Female, 34 years old, diagnosed non-Hodgkin’s lymphoma (NHL) for 3 and a half years. Pathology: Diffuse size cells mixed with non-Hodgkin’s lymphoma. CHOP regimen was used for 2 cycles of chemotherapy, and no retreatment was given after achieving complete remission (CR). 20 months ago lymph nodes on both sides of the neck enlargement, pathology with the former. The CHOP regimen and the PYM-CHOP regimen were followed for 10 cycles of chemotherapy, and local radiotherapy was performed six months ago, all of which did not reach CR. In the case of poor efficacy of conventional chemotherapy, it was decided to use G-CSF (Well Blood) to support large-dose chemotherapy. The program is BEOD-CTX. Specific medications are as follows: CTX; 2.0, 1 to 13 days, static (Mesna protects the kidneys); VCR: 1.5 mg, Day 1, intravenous; BCNU: 375 mg, Day 1, Insulin; V_p—16: 100 mg ,